- Companies
- Zap Surgical Systems
Zap Surgical Systems Funding, Investors & Competitors
Zap Surgical Systems has raised $159M across 2 funding rounds, most recently a $78M Series E in November 2024.
Last Zap Surgical Systems funding round
$78M
Series E · Nov 2024
Cumulative funding Zap Surgical Systems raised
$159M
across 2 funding rounds
Key investors in Zap Surgical Systems
Foxconn
Primavera Capital Group
Shangbay Capital
Varian
GT Healthcare Capital Partners
Chow Tai Fook
Baheal Pharmaceutical Group
About Zap Surgical Systems
Zap Surgical Systems is a San Carlos-headquartered medical device company manufacturing the ZAP-X gyroscopic radiosurgery platform. The self-shielded system delivers stereotactic treatments without vault construction, suiting outpatient centers and physician offices. FDA-cleared in 2020, ZAP-X treats brain tumors and trigeminal neuralgia using a 3 Tesla MRI-integrated linear accelerator. Installations operate in the US, China, and Europe.
Founded
2014
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales, Subscription
Zap Surgical Systems Funding History
Zap Surgical Systems has raised a total of $159M across 2 funding rounds.
Zap Surgical Systems' first fundraising round was a $81M undisclosed-stage round in January 2020. The most recent completed round was a $78M Series E in November 2024.
Zap Surgical Systems funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Nov 2024 | Series E | Baheal Pharmaceutical Group (lead) | $78M | Zap Surgical Systems, founded by John R. Adler MD in 2014 and headquartered in San Carlos, CA, develops the ZAP-X Gyroscopic Radiosurgery platform, a non-invasive robotic system for precise brain tumor treatment without needing shielded rooms or radioactive isotopes. The vault-free, cobalt-free design enables gyroscopic beam delivery from thousands of angles to target intracranial diseases while sparing healthy tissue. ZAP-X received US registration in 2017, China's innovative device approval in 2018, and full marketing approval in China in June 2023, with installations for clinical trials at institutions like the People's Liberation Army General Hospital. On approximately November 8, 2024, Zap Surgical closed a $78 million Series E funding round led by Qingdao Baheal Medical (part of Baheal Pharmaceutical Group), with participation from other strategic investors. The funds aim to accelerate manufacturing, sales, distribution, and commercialization of ZAP-X globally, addressing access gaps where only about 200,000 of over 5 million potential patients receive optimal stereotactic radiosurgery annually due to legacy technology costs. Baheal previously invested via equity as part of a July 2024 strategic partnership. The partnership extends beyond funding: Baheal gained exclusive commercialization rights for ZAP-X in mainland China, Hong Kong, and Macau, announced November 25, 2024, and a Baheal subsidiary will handle large-scale production for Chinese and global markets. This aligns with Baheal's expansion into precision radiotherapy, building on their linear accelerator investments. Prior funding totals around $245.5M over multiple rounds, with investors including Chow Tai Fook Enterprises, Foxconn, and Varian Medical Systems. |
| Jan 2020 | Undisclosed stage | Primavera Capital Group (lead); Foxconn; Chow Tai Fook; Shangbay Capital; GT Healthcare Capital Partners; Varian | $81M | ZAP Surgical Systems, Inc. is a medical technology company developing the ZAP-X gyroscopic radiosurgical robot, a next-generation system for non-invasive tumor ablation, particularly for treating brain, head, and neck cancers. The company announced the completion of an $81 million equity financing round on January 8 or 9, 2020, led by Primavera Capital Group, with participation from new investors GT Healthcare Capital Partners, Chow Tai Fook Enterprises, ShangBay Capital, and Hogy Medical, alongside existing investors Foxconn Technology Group and Varian Medical Systems. This brought the company's total financing to over $160 million to date, with funds earmarked to accelerate commercialization of the FDA-cleared ZAP-X robot. The company was in early commercial development post-FDA clearance, focusing on global expansion for stereotactic radiosurgery to treat over 2 million annual untreated cases. Primavera's involvement highlights their healthcare focus, with co-head Johnny Zou on ZAP Surgical's board. |
Who has invested in Zap Surgical Systems?
7 investors have backed Zap Surgical Systems across its funding rounds, including Foxconn, Primavera Capital Group, Shangbay Capital, Varian, GT Healthcare Capital Partners and Chow Tai Fook.
Lead investors include Baheal Pharmaceutical Group and Primavera Capital Group.
Zap Surgical Systems Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 1 | Participant | Jan 2020 | ||
| 1 | Participant | Jan 2020 | ||
| 1 | Participant | Jan 2020 | ||
| 1 | Lead | Jan 2020 | ||
| 1 | Lead | Nov 2024 | ||
This data is available for Pro users. Sign up to see all 7 Zap Surgical Systems investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialZap Surgical Systems Competitors
Zap Surgical Systems competitors include listed companies like IDEXX Laboratories, GE HealthCare, United Imaging and Glaukos, and private ones like Dental Monitoring and AcuityMD.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $955M | - |
Zap Surgical Systems Public Comps
Zap Surgical Systems is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Zap Surgical Systems competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Zap Surgical Systems
| When was Zap Surgical Systems founded? | Zap Surgical Systems was founded in 2014. |
| Where is Zap Surgical Systems headquartered? | Zap Surgical Systems is headquartered in San Francisco, CA, United States. |
| Is Zap Surgical Systems publicly listed? | No, Zap Surgical Systems is a private, VC-backed company. |
| How much funding has Zap Surgical Systems raised? | Zap Surgical Systems has raised $159M across 2 funding rounds. |
| What was Zap Surgical Systems' last funding round? | Zap Surgical Systems' last funding round was a $78M Series E in November 2024, led by Baheal Pharmaceutical Group. |
| Who are Zap Surgical Systems' investors? | Zap Surgical Systems' investors include Foxconn, Chow Tai Fook, Shangbay Capital, Primavera Capital Group, Baheal Pharmaceutical Group, GT Healthcare Capital Partners and Varian. |
| Which companies are comparable to Zap Surgical Systems? | Companies comparable to Zap Surgical Systems include IDEXX Laboratories, GE HealthCare, United Imaging, Glaukos, Dental Monitoring and AcuityMD. |
See companies similar to Zap Surgical Systems
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




